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Abstract
Background: Maternal obesity may program the fetus and increase the susceptibility of the offspring to adult
diseases. Metformin crosses the placenta and has been associated with decreased inflammation and reversal of
fatty liver in obese leptin-deficient mice. We investigated the effects of metformin on maternal and fetal lipid
metabolism and hepatic inflammation using a rat model of diet-induced obesity during pregnancy.
Methods: Female Wistar rats (6–7 weeks old) were fed normal or high calorie diets for 5 weeks. After mating with
normal-diet fed males, half of the high calorie-fed dams received metformin (300 mg/kg, daily); dams (8 per group)
continued diets through gestational day 19. Maternal and fetal livers and fetal brains were analyzed for fatty acids
and for fatty acid metabolism-related gene expression. Data were analyzed by ANOVA followed by Dunnett’s post
hoc testing.
Results: When compared to control-lean maternal livers, obesogenic-diet-exposed maternal livers showed significantly
higher saturated fatty acids (14:0 and 16:0) and monounsaturated fatty acids (16:1n7 and 18:1n9) and lower
polyunsaturated (18:2n6 and 20:4n6 [arachidonic acid]) and anti-inflammatory n3 polyunsaturated fatty acids
(18:3n3 and 22:6n3 [docosahexaenoic acid]) (p < 0.05). Metformin did not affect diet-induced changes in
maternal livers. Fetal livers exposed to the high calorie diet showed significantly increased saturated fatty
acids (18:0) and monounsaturated fatty acids (18:1n9 and 18:1n7) and decreased polyunsaturated fatty acids
(18:2n6, 20:4n6 and 22:6n3) and anti-inflammatory n3 polyunsaturated fatty acids, along with increased gene
expression of fatty acid metabolism markers (Fasn, D5d, D6d, Scd1, Lxrα). Metformin significantly attenuated diet-induced
inflammation and 18:1n9 and 22:6n3 in fetal livers, as well as n3 fatty acids (p < 0.05). Prenatal obesogenic diet exposure
significantly increased fetal liver IFNγ levels (p < 0.05), which was reversed by maternal metformin treatment (p < 0.05).
Conclusions: Consumption of a high calorie diet significantly affected maternal and fetal fatty acid metabolism. It
reduced anti-inflammatory polyunsaturated fatty acids in maternal and fetal livers, altered gene expression of fatty acid
metabolism markers, and induced inflammation in the fetal livers. Prenatal metformin attenuated some diet-induced
fatty acid changes and inflammation in the fetal livers without affecting maternal livers, suggesting that maternal
metformin may impact fetal/neonatal fatty acid/lipid metabolism.
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Background
The prevalence of obesity and diabetes has increased in the
US and globally [1–3]. Data from 2013 to 2014 reveals that
over 40 % of women in the US are obese (BMI ≥ 30) and
over 9 % are morbidly obese (BMI ≥ 40) – representing a
linear increase since 2005 [4, 5]. Pregnancy itself is charac-
terized by increased insulin resistance, which is more severe
in gestational diabetes mellitus (GDM). Maternal obesity
and GDM, along with their accompanying metabolic/lipid,
vascular, and inflammatory changes [6] are associated with
an increased risk of poor pregnancy outcomes [7–9], as
well as an increased risk of type 2 diabetes [10, 11] and car-
diovascular disease in the future [12, 13]. In addition, mater-
nal obesity and aberrant glucose and lipid metabolism may
program the fetus for hepatic lipid dysfunction and may in-
crease the susceptibility of the offspring to adult diseases/
conditions, including metabolic syndrome-like phenotype
and poor vascular health [14–17].
In the US, insulin has been considered the standard
therapy for GDM [18]. Metformin, a biguanide drug that
promotes glucose uptake and inhibits liver gluconeogen-
esis, is increasingly being used during pregnancy, but is
not approved by the US Food and Drug Administration
for use in GDM. In the absence of pregnancy, evidence
for improved lipid metabolism by metformin has been
accumulating [19, 20]. In fact, metformin treatment re-
versed fatty liver disease in obese leptin-deficient mice
[21]. Because metformin crosses the placenta [22, 23]
and thus, could impact both maternal and fetal metabol-
ism, we investigated the effects of prenatal metformin ad-
ministration on maternal and fetal lipid metabolism and
hepatic inflammation using a rat model of diet-induced
obesity and metabolic syndrome during pregnancy.
Methods
Experimental animals
The Institutional Animal Care and Use Committee
(IACUC) approved all animal studies prior to animal
experimentation (#2010-031). All animal experimenta-
tion was performed in accordance with the Public
Health Service (PHS) Policy on Humane Care and Use
of Laboratory Animals and euthanasia complied with
the American Veterinary Medical Association (AVMA)
Panel on Euthanasia. Female Wistar rats (6–7 weeks
old, Taconic, Germantown, NY) were acclimatized with
free access to standard rat chow and water for at least 72 h.
As previously described [24], rats were randomly assigned
to one of two ad libitum diets: (1) a control rat chow or
normal-fed (NORM) or (2) a high calorie diet (HCAL, con-
sisting of 33 % ground commercial rat chow, 33 % full fat
sweetened condensed milk, 7 % sucrose, and 27 % water)
shown to induce GDM and metabolic syndrome in rats
[24, 25]. After 5 weeks, lean and acutely obese female rats
(maintained on their respective diets) were mated with
normal-fed male Wistar rats (9–14 weeks old, Taconic).
On gestation day 1 (GD1), one half of the dams fed the
high calorie diet received metformin (300 mg/kg, p.o.
daily). All dams (NORM, n = 8; HCAL, n = 8; HCAL+met-
formin, n = 8) continued their respective diets throughout
gestation. On GD19 dams were euthanized by CO2 inhal-
ation followed by exsanguination and livers were collected.
Fetuses, delivered by cesarean section were euthanized by
decapitation and fetal livers and brains were collected. Ma-
ternal livers, fetal livers and fetal brains were flash frozen in
liquid nitrogen and stored at −80 °C.
Lipid and fatty acid (FA) profiling
Lipids were extracted from the maternal livers and fetal
livers and brains according to the method of Folch–Lees
[26]. Individual fatty acids (FAs) of the triglyceride frac-
tions (maternal and fetal livers) or phospholipid fractions
(fetal brains) were quantified at the Lipid Core Laboratory
of Vanderbilt University’s Mouse Metabolic Phenotyping
Center (Grant #DK59637), as previously described [27].
Total triglyceride-associated FAs of the maternal and fetal
livers were normalized to liver weights (μg/mg); FA sub-
sets and individuals FAs were expressed as percent of total
fraction (mg/100 mg triglyceride-fatty acids (maternal and
fetal livers) or phospholipid fatty acids (fetal brains)).
Expression of markers of FA metabolism
Markers of FA synthesis and metabolism in maternal
and fetal livers and fetal brains were assessed by quanti-
tative polymerase chain reaction (qPCR) methods, as
previously described [28]. RNA was isolated using the
RNeasy® Plus Universal Mini kit with DNase treatment
(Qiagen, Foster City, CA); RNA samples had 260/280
and 260/230 ratios ≥1.9. qPCR reactions were performed
(in triplicate) using rat specific primers (designed using
the Roche Universal Probe Library Design Center) and
synthesized by Eurofins (Huntsville, AL) for rat desaturase
and elongase-related genes: D5d, D6d, Scd1, Elovl1, Elovl2,
Elovl5, and Elovl6 and other genes involved in FA synthe-
sis: Chrebp (also known as Mlxipl), Lxra, Lxrb, Srebf1,
and Fasn, using the Eurogentec One Step RT qPCR mas-
termix (AnaSpec, Fremont, CA), 100 ng RNA, Roche Uni-
versal Library probes (Indianapolis, IN) and the Roche
480 Light Cycler, as previously described [29]. See Table 1
for qPCR primers and probes. Changes in mRNA expres-
sion (corrected using rat Hprt1 as the housekeeping gene)
were calculated using the comparative Ct (ΔΔCt) method
[30]. Data are presented as relative mRNA expression with
the normal-fed group set to 1.0.
Evaluation of cytokines and chemokines in maternal and
fetal livers
Maternal and fetal livers were analyzed for multiple cy-
tokines using the rat 9-plex pro-inflammatory panel
Harris et al. Nutrition & Metabolism  (2016) 13:55 Page 2 of 13
assay kit (Meso Scale Diagnostics [MSD], Rockville,
MD), as previously described [31]. Liver homogenates
were assayed for cytokines (IFNγ, IL-1β, IL-4, IL-5, IL-6,
IL-10, IL-13, and TNFα) and chemokines (CXCL1,
CXC-motif ligand 1) using the MSD multiplex platform.
The raw data were measured as electrochemilumines-
cence signals with the MSD Sector Imager 2400 plate
reader (Meso Scale Diagnostics, Rockville, MD) and ana-
lyzed using the Discovery Workbench 3.0 software
(MSD). The lower limits of detection for the analytes in
this assay were ≤2 pg/ml, except for: IL-1β (7 pg/ml), IL-
5 and IL-6 (14 pg/ml), and IL-10 (20 pg/ml). The R2
value for each standard curve was between 0.99 and 1.0.
Samples being compared were run on the same plate
and the % coefficient of variation of control replicates
run on the same plate was between 2.3 % (TNFα) and
5.7 % (IFNγ). Liver cytokine data were corrected for pro-
tein concentration (Bio-Rad protein assay, Bio-Rad,
Hercules, CA) and expressed as pg/g.
Western blotting
ChREBP and SREBP-1 protein expression in maternal and
fetal livers was assessed by western blotting. Liver tissues
(100 mg) were homogenized as described above. Proteins
(40 μg/lane, determined by BioRad protein assay) were
separated by electrophoresis using Nu-PAGE® gels (Life
Technologies, Grand Island, NY) and transferred to
PVDF membranes (Millipore). The blots were probed
with anti-SREBP-1 (Santa Cruz Biotechnology, Dallas TX),
anti-ChREBP (Novus Biologicals, Littleton, CO), and anti-
GAPDH (Cell Signaling Technology, Danvers, MA, USA)
antibodies, followed by near infrared-fluorescently labeled
secondary antibodies (LI-COR, diluted 1:15,000), and re-
vealed using the Odyssey infrared imaging system (LI-
COR Biosciences), as previously described [28, 32]. Band
densities (SREBP-1: GAPDH and ChREBP:GAPDH) were
assessed using Image J software (NIH).
Statistics
Data were analyzed using one-way ANOVAs for mul-
tiple comparisons followed by Dunnett’s post-hoc
testing using GraphPad Prism 5.03 (GraphPad Soft-
ware, San Diego, CA). P values <0.05 were consid-
ered significant.
Results
High calorie diet alters maternal liver lipid profiles: no
effect of metformin
Livers obtained from the HCAL-fed dams showed a 40 %
increase in total triglyceride-associated FAs vs. control dam
livers, irrespective of metformin treatment (Fig. 1a, p < 0.05).
Furthermore, maternal livers showed numerous HCAL-diet
related changes in their FA profiles; HCAL-exposed livers
had significantly higher saturated fatty acids (SFAs) (Fig. 1b,
p < 0.05) and monounsaturated fatty acids (MUFAs) (Fig. 1c,
p < 0.001) and lower polyunsaturated fatty acids (PUFAs)
(Fig. 1d, p < 0.001), as well as a 3-fold lower expression of
anti-inflammatory n3 FAs compared to control-fed dams
(Fig. 1e, p < 0.001). More specifically, maternal HCAL livers
had significantly higher 14:0, 16:0, 16:1n7, and 18:1n9
FAs and significantly lower 18:2n6, 18:3n3, 20:4n6 (ara-
chidonic acid, AA) and 22:6n3 (docosahexaenoic acid,
DHA) FAs, when compared to livers obtained from
control-fed dams (Table 2). Maternal metformin treat-
ment did not affect HCAL-diet-induced triglyceride-FA
levels or FA-related changes in the maternal livers
(Fig. 1a-e and Table 2).
Maternal obesogenic diet affects markers of lipid
metabolism in maternal livers
Srebf1 mRNA expression was significantly induced in
the maternal livers following HCAL diet exposure
(Table 3, p < 0.001). However, maternal metformin ad-
ministration did not alter HCAL-induced Srebf1 mRNA
expression in the maternal livers (Table 3). There were
no significant changes in the mRNA expression of other
markers of lipid synthesis/metabolism analyzed (Chrebp,
Lxrα/β, Srebf1, and Fasn, as well as various elongases
Table 1 qPCR primers used to assess gene expression of markers
of lipid/fatty acid metabolism

























































Forward and reverse primers for rat genes with GenBank Accession numbers
and specific Roche Universal Probe numbers used for assessing mRNA
expression in rat tissues by qPCR
aNational Center for Biotechnology Information
(NCBI) EntrezGene (http://www.ncbi.nlm.nih.gov/gene)
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(Elovl2, 5, or 6) and desaturases (D5d, D6d, D9d [Scd1])) in
the maternal livers following the HCAL diet (±metformin)
(Table 3). Next, we confirmed the increased expression of
SREBP-1 protein in maternal livers following HCAL diet
exposure when compared to controls (Fig. 2a and b,
p < 0.001); the increased SREBP-1 protein expression
was partially attenuated by metformin administration
(Fig. 2a and b, p < 0.05). By contrast, maternal liver
ChREBP protein expression was unaffected by HCAL-
diet exposure (± metformin) (Fig. 2a and b).
HCAL diet prior to and during pregnancy did not
promote cytokine production in maternal livers
Based on the link between hepatic liver lipid accumulation
and inflammation, we assessed maternal livers obtained
from control-fed and HCAL-fed (±metformin) dams for
numerous cytokines. We found no effect of the HCAL
diet (with or without metformin) on localized hepatic in-
flammation, as determined by measuring IL-1β, IL-4, IL-5,
IL-6, IL-10, IL-13, IFNγ, TNFα, and CXCL1 concentra-
tions in the maternal livers (Additional file 1: Table S1).
Fig. 1 HCAL diet increases triglyceride deposition in the maternal liver and alters maternal liver lipid profiles. No effect of metformin. Dams were
fed a normal (NORM) or a high calorie (HCAL) diet prior to and during pregnancy ±metformin (MET), as described in the Methods. Maternal liver
total triglyceride-associated FA (TG-FA) concentrations were determined on GD19 (a). Saturated fatty acids (SFA, b), monounsaturated FA (MUFA,
c), polyunsaturated FA (PUFA, d), and n3 fatty acids (n3FA, e) profiles of the maternal livers were determined on GD19. Data are shown as mean
± SD. *p < 0.05; **p < 0.01; ***p < 0.001
Table 2 HCAL diet affects maternal liver fatty acid profiles. No
effect of metformin






SFA 14.0 0.6 (±0.14) 1.3 (±0.24)a** 1.2 (±0.20)
16.0 28.5 (±1.90) 32.7 (±2.35)a* 33.4 (±2.25)
18.0 6.7 (±0.44) 6.3 (±1.89) 6.5 (±0.60)
MUFA 16.1n7 2.1 (±0.47) 4.2 (±0.89)a* 3.7 (±0.47)
18.1n9 33.2 (±1.43) 41.4 (±1.04)a* 41.3 (±1.79)
18.1n7 4.1 (±0.29) 4.4 (±0.44) 4.2 (±0.74)
PUFA 18.2n6 19.5 (±2.60) 8.3 (±1.41)a* 8.1 (±1.10)
18.3n3 0.8 (±0.10) 0.3 (±0.19)a* 0.2 (±0.21)
20.4n6 2.6 (±0.74) 1.1 (±0.34)a* 1.1 (±0.39)
22.6n3 1.6 (±0.63) 0.3 (±0.23)a* 0.2 (±0.22)
NORM normal diet, HCAL high calorie diet, MET metformin, SD standard
deviation, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA
polyunsaturated fatty acids
aNORM vs. HCAL; *p < 0.05, **p < 0.01
Data are expressed as mean ± SD (mg/100 mg)
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Fetal exposure to maternal obesity significantly alters
fetal hepatic FA profile; metformin reverses some of
these effects
Although in utero exposure to the HCAL diet did not
significantly change the total triglyceride-associated FA
content of the fetal livers on embryonic day 19 (Fig. 3a),
it significantly increased SFAs (Fig. 3b, p < 0.01) and
MUFAs (Fig. 3c, p < 0.001), and significantly decreased
PUFAs (Fig. 3d, p < 0.001), as well as anti-inflammatory
n3 FAs when compared to control fetal livers (Fig. 3e,
p < 0.001). More specifically, livers obtained from HCAL
diet-exposed fetuses showed significantly increased 18:0,
18:1n9, and 18:1n7 and significantly reduced 18:2n6, 20:4n6
(AA), and 22:6n3 (DHA) (Table 4). While no changes in
maternal hepatic FA profiles were observed following met-
formin administration (Fig. 1b–e and Table 2), significant
changes in diet-induced FA changes in the fetal livers were
observed following maternal metformin treatment. HCAL-
induced overall MUFAs (Fig. 3c, p < 0.001), specifically
18:1n9, were significantly attenuated by maternal met-
formin administration (Table 4, p < 0.01), while HCAL-
induced 18:1n7 was only slightly reduced (not significant)
(Table 4). Maternal metformin blocked HCAL-reduced
22:6n3 (DHA) in fetal livers following HCAL-exposure
(Table 4, p < 0.05). Similarly, HCAL-suppressed n3 FA
levels in the fetal livers were reversed by maternal metfor-
min treatment (Fig. 3e, p < 0.001).
In utero exposure to maternal high calorie diet alters
markers of lipid metabolism in fetal livers
Fetal exposure to the maternal HCAL-diet significantly
increased the expression of several genes shown to be
involved in fatty acid metabolism in the fetal livers, in-
cluding D5d, D6d, D9d [Scd1], Fasn, and Lxrα (Table 3).
In utero metformin exposure did not significantly attenu-
ate these effects; however, metformin slightly (not signifi-
cantly) reduced the effects of HCAL diet exposure on D5d
and D9d (Scd1) mRNA expression in fetal livers when
assessed on embryonic day 19 (Table 3). Western blotting
of fetal livers confirmed that neither SREBP-1 nor
ChREBP protein expression was affected by HCAL diet
(with or without metformin) (Fig. 4a–b).
In utero exposure to maternal obesogenic diet
significantly affects fetal brain FA profiles
While fetal brains had no significant differences in over-
all phospholipid-associated SFA, MUFA, PUFA, or n3
FA concentrations following HCAL-diet exposure when
compared to controls (Fig. 5a–d), HCAL diet-exposed
fetal brains had significantly reduced 20:4n6 (AA), 22:4n6,
and 22:5n6 and significantly increased 22:6n3 (DHA) con-
centrations when compared to controls (Table 5). With
the exception of HCAL-reduced 22:5n6 in the fetal brains,
which was reversed by maternal metformin treatment
(p < 0.05), no other changes were observed following ma-
ternal metformin administration (Table 5). Fetal exposure
to the HCAL-diet reduced D9d (Scd1) mRNA expression
in the fetal brains (Table 6, p < 0.05), but maternal metfor-
min had no effect on D9d (Scd1) mRNA expression
(Table 6).
Prenatal exposure to metformin reduces HCAL diet-
induced IFNγ levels in fetal livers
Although no effect of the HCAL diet was found on ma-
ternal liver inflammation, as assessed by measuring vari-
ous cytokines and chemokines (see Additional file 1:
Table S1), in utero exposure to the maternal obesogenic
diet significantly increased IFNγ concentrations in the
Table 3 The effects of high calorie diet (± metformin) on gene expression in maternal and fetal livers
Maternal livers Fetal Livers
Gene NORM mean (±SD) HCAL mean (±SD) HCAL +MET mean (±SD) NORM mean (±SD) HCAL mean (±SD) HCAL +MET mean (±SD)
Chrebp 1.0 (±0.33) 0.9 (±0.19) 1.1 (±0.41) 1.0 (±0.25) 1.1 (±0.34) 0.9 (±0.46)
D5d 1.0 (±0.36) 1.2 (±0.23) 1.4 (±0.27) 1.0 (±0.34) 1.5 (±0.44)a* 1.4 (±0.34)
D6d 1.0 (±0.49) 1.1 (±0.33) 1.5 (±0.26) 1.0 (±0.31) 1.5 (±0.23)a*** 1.6 (±0.26)
D9d (Scd1) 1.0 (±0.68) 1.2 (±0.35) 1.3 (±0.33) 1.0 (±0.33) 1.4 (±0.37)a* 1.2 (±0.28)
Elovl2 1.0 (±0.39) 0.9 (±0.24) 0.8 (±0.13) 1.0 (±0.23) 1.1 (±0.30) 1.0 (±0.32)
Elovl5 1.0 (±0.14) 1.0 (±0.24) 1.1 (±0.06) 1.0 (±0.12) 1.5 (±0.86) 1.1 (±0.18)
Elovl6 1.0 (±0.37) 0.8 (±0.26) 1.0 (±0.43) 1.0 (±0.15) 1.1 (±0.16) 1.3 (±0.25)
Fasn 1.0 (±0.46) 1.0 (±0.47) 1.1 (±0.39) 1.0 (±0.18) 1.5 (±0.28)a*** 1.6 (±0.37)
Lxrα 1.0 (±0.13) 1.0 (±0.09) 1.1 (±0.14) 1.0 (±0.13) 1.2 (±0.30)a** 1.3 (±0.30)
Lxrβ 1.0 (±0.42) 1.0 (±0.11) 1.0 (±0.13) 1.0 (±0.13) 1.0 (±0.14) 1.0 (±0.13)
Srebf1 1.0 (±0.29) 1.8 (±0.36)a*** 1.7 (±0.38) 1.0 (±0.23) 1.3 (±0.40) 1.2 (±0.19)
NORM normal diet, HCAL high calorie diet, MET metformin, SD standard deviation
aNORM vs. HCAL; *p = <0.05; **p < 0.01, ***p < 0.001
Data are presented as relative mRNA expression (mean ± SD), with the normal-fed group set to 1.0
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fetal livers (Fig. 6 and Additional file 1: Table S1). This
effect was attenuated by prenatal metformin exposure
(Fig. 6 and Additional file 1: Table S1).
Discussion
Obesity in pregnant women is accompanied by dyslipid-
emia, characterized by elevated triglyceride levels [6].
Consumption of the HCAL diet enriched in saturated
fats and sugar by pregnant rats significantly increased
total triglycerides and increased proportion of SFAs, and
MUFAs, and decreased PUFAs and n3 FAs in maternal
rat livers (Fig. 1 and Table 2). The most notable changes in
the maternal livers were the >2-fold decline in PUFAs
(Fig. 1d) and the 3-fold decline in anti-inflammatory n3
FAs (Fig. 1e). These changes might be detrimental, as ma-
ternal PUFAs are essential for healthy fetal development,
including the fetal brain [33] and because n3 FAs have been
proposed to regulate fetal brain development [34] and im-
prove insulin resistance during pregnancy [35]. Likewise,
the accumulation of the end product of de novo lipogen-
esis, 18:1n9 (oleic acid), was significantly higher in the
HCAL-exposed maternal livers when compared to control
maternal livers (Table 2). These changes, indicative of liver
dysfunction and enhanced de novo lipogenesis, were ac-
companied by elevated Srebf mRNA expression (almost 2-
fold, Table 3) and increased SREBP-1 protein (Fig. 2a–b) in
the maternal livers following the obesogenic diet. SREBP-1
serves as one of the major regulators of de novo lipogen-
esis/fatty acid synthesis by activating genes required for
lipogenesis [36, 37]. In fact, overexpression of SREBP-1 in
transgenic mice produced fatty livers via excess de novo
lipogenesis [38]. Hepatic triglyceride deposition and meta-
bolic syndrome have been strongly associated with insulin
resistance [39, 40]. Both insulin and glucose are the major
inducers of Srebf mRNA expression, and thus, these results
are consistent with previous studies showing that this obe-
sogenic diet induces GDM [25] and metabolic syndrome,
as determined by increased maternal circulating insulin,
leptin, and triglyceride levels [24].
Maternal obesity and metabolic syndrome can lead to
adverse fetal outcomes, including structural anomalies and
fetal liver lipotoxicity [41, 42]. Fetal exposure to excess ma-
ternal lipids and their metabolites are proposed to trigger
signaling pathways in developing organs, including the
liver, adipose, skeletal muscle, and brain, that lead to short-
and long-term metabolic consequences (e.g., energy stor-
age, cell differentiation, cell death, and inflammation)
(Reviewed in [41]). We found that in utero HCAL expos-
ure did not affect total triglyceride-associated fatty acids in
the fetal livers, but it significantly increased the proportion
of SFAs and MUFAs, decreased PUFAs and n3 FAs
(Fig. 3b–e and Table 4), and elevated IFNγ in the fetal
Fig. 2 SREBP-1 protein in the maternal liver is increased by the HCAL diet. Maternal livers obtained from dams after feeding normal (NORM) or high
calorie (HCAL) diets (±metformin, MET) were examined on GD19 for SREBP-1 and ChREBP protein expression by western blotting (a). Quantitation
of SREBP-1 and ChREBP bands normalized for GAPDH expression (SREBP-1:GAPDH and ChREBP:GAPDH) is shown in b. Data are shown as mean ±
SD. *p < 0.05; ***p < 0.001
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Table 4 HCAL diet (±metformin) exposure alters FA profiles of fetal livers
Fatty acid NORM mean (±SD) HCAL mean (±SD) HCAL +MET mean (±SD)
SFA 14.0 2.1 (±0.18) 2.2 (±0.27) 2.1 (±0.23)
16.0 23.9 (±0.96) 25.6 (±1.57) 25.4 (±1.94)
18.0 7.18 (±0.73) 8.8 (±0.87)a*** 9.2 (±0.76)
MUFA 16.1n7 4.3 (±0.45) 4.6 (±0.46) 3.9 (±0.29)
18.1n9 34.2 (±1.56) 38.8 (±2.08)a** 35.9 (±2.26)b**
18.1n7 3.6 (±0.28) 4.4 (±0.20)a*** 4.2 (±0.17)
PUFA 18.2n6 14.4 (±2.1) 8.8 (±1.70)a*** 10.1 (±0.92)
18.3n6 0.5 (±0.26) 0.4 (±0.21) 0.22 (±0.28)
20.4n6 2.2 (±0.69) 1.4 (±0.43)a* 1.7 (±0.31)
22.6n3 6.8 (±1.02) 5.0 (±1.76)a* 7.0 (±1.21)b*
NORM normal diet, HCAL high calorie diet, MET metformin, SD standard deviation, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA
polyunsaturated fatty acids
aNORM vs. HCAL, bHCAL vs. HCAL +MET; *p < 0.05, **p < 0.01, ***p < 0.001
Data are expressed as mean ± SD (mg/100 mg)
Fig. 3 HCAL diet exposure alters fetal liver fatty acid profiles. Modifications by in utero metformin exposure. Fetuses were exposed to either a normal
(NORM) or a high calorie (HCAL) maternal diet (±metformin, MET), as described in the Methods. Fetal liver total triglyceride-associated fatty acid
(TG-FA) concentrations (a), saturated fatty acids (SFA, b), monounsaturated FA (MUFA, c), polyunsaturated FA (PUFA, d), and n3 FA (e) profiles of
the fetal livers were determined on embryonic day 19. Data are shown as mean ± SD.*p < 0.05; ***p < 0.001
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Fig. 4 SREBP-1 and ChREBP protein expression in the fetal livers are unaffected by exposure to the HCAL diet. No effect of metformin. Fetal livers were
examined for SREBP-1 and ChREBP protein expression by western blotting (a). Quantitation of SREBP-1 and ChREBP bands normalized for GAPDH
expression (SREBP-1:GAPDH and ChREBP:GAPDH) are shown in b
Fig. 5 Effect of HCAL diet exposure on fetal brain fatty acid profiles. No effect of metformin. Fetuses were exposed to either a normal (NORM) or a
high calorie (HCAL) maternal diet (±metformin, MET), as described in the Methods. The saturated fatty acids (SFA, a), monounsaturated FA (MUFA,
b), polyunsaturated FA (PUFA, c), and n3 FA (d) profiles of the fetal brains were determined on embryonic day 19. Data are shown as mean ± SD
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livers (Fig. 6). IFNγ, previously shown to accompany hep-
atic steatosis in mice [43], may directly induce endoplas-
mic reticulum stress, a potential contributor to the vicious
cycle of obesity and chronic inflammation [35]. HCAL
diet-exposed fetal livers showed enhanced Lxra mRNA ex-
pression (Table 3). Lxrα is considered the master regulator
of hepatic lipogenesis; it induces Fasn [36, 37]. We ob-
served enhanced Fasn, D5d, D6d, and D9d mRNA expres-
sion in the HCAL-exposed fetal livers (Table 3), consistent
with previous studies showing altered FA metabolism and
lipid accumulation in the fetal livers of non-human pri-
mates following exposure to a chronic maternal high fat
diet [42].
Aberrant FA profiles found in the fetal brains follow-
ing in utero HCAL-diet exposure (decreased 20:4n6,
22:4n6, and 22:5n6 (PUFAs), Table 5) were consistent
with decreased PUFAs in the maternal and fetal livers
(Figs. 1 and 3, Tables 2 and 4). Surprisingly, fetal brains
exposed to the HCAL diet showed increased 22:6n3
(DHA) (Table 5). DHA, which is primarily obtained via
transplacental transport from the maternal side, is critic-
ally important for fetal brain development [33]. Maternal
liver DHA levels were more reduced by the HCAL diet
when compared to those in the fetal liver. Thus, the ob-
served increase in fetal brain DHA levels may represent
a fetal compensatory mechanism to obtain DHA from
the maternal compartment to protect the fetal brain des-
pite reduced DHA availability and reduced fetal liver
DHA levels.
Table 5 Effects of maternal HCAL diet (±metformin) on fetal brain FA profiles
Fatty acid NORM mean (±SD) HCAL mean (±SD) HCAL +MET mean (±SD)
SFA 14.0 1.9 (±0.08) 2.0 (±0.05) 2.0 (±0.23)
16.0 33.4 (±0.89) 33.6 (±0.93) 32.8 (±0.27)
18.0 17.8 (±0.81) 17.5 (±0.52) 16.9 (±0.30)
MUFA 16.1n7 2.2 (±0.21) 2.2 (±0.10) 2.3 (±0.12)
18.1n9 13.6 (±0.56) 13.9 (±0.30) 14.3 (±0.39)
18.1n7 3.9 (±0.19) 3.9 (±0.26) 4.0 (±0.21)
PUFA 20.4n6 13.2 (±0.42) 12.5 (±0.35)a* 13.0 (±0.41)
22.4n6 3.2 (±0.12) 2.9 (±0.03)a** 3.0 (±0.17)
22.5n6 2.9 (±0.24) 2.3 (±0.22)a** 2.7 (±0.22)b*
22.6n3 7.0 (±0.75) 8.6 (±1.53)a* 8.0 (±0.35)
NORM normal diet, HCAL high calorie diet, MET metformin, SD standard deviation, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA
polyunsaturated fatty acids
aNORM vs. HCAL,b HCAL vs. HCAL +MET; *p < 0.05, **p < 0.01
Data are expressed as mean ± SD (mg/100 mg)
Table 6 The effects of HCAL diet (± metformin) on gene







Chrebp ND ND ND
D5d 1.0 (±0.14) 0.9 (±0.13) 1.0 (±0.19)
D6d 1.0 (±0.06) 0.9 (±0.12) 1.1 (±0.09)
D9d (Scd1) 1.0 (±0.06) 0.9 (±0.11)a*** 0.8 (±0.05)
Elovl2 1.0 (±0.10) 1.4 (±0.42) 1.5 (±0.08)
Elovl5 1.0 (±0.20) 1.0 (±0.14) 1.0 (±0.10)
Elovl6 1.0 (±0.15) 0.9 (±0.17) 1.1 (±0.16)
Fasn 1.0 (±0.13) 1.0 (±0.07) 1.0 (±0.10)
Lxrα 1.0 (±0.01) 1.2 (±0.07) 1.4 (±0.29)
Lxrβ 1.0 (±0.19) 0.9 (±0.09) 0.8 (±0.22)
Srebf1 1.0 (±0.14) 1.1 (±0.23) 1.0 (±0.27)
NORM normal diet, HCAL high calorie diet, MET metformin, SD standard deviation
aNORM vs. HCAL; ***p < 0.001
Data are presented as relative mRNA expression (mean ± SD), with the normal-fed
group set to 1.0
Fig. 6 Intrauterine exposure to HCAL diet increases fetal liver IFNγ
levels. Metformin attenuates enhanced IFNγ levels in fetal livers. Fetal
livers were obtained following exposure to maternal normal (NORM) or
high calorie (HCAL) diets (±metformin, MET) on embryonic day 19 and
IFNγ levels were assessed and adjusted for fetal liver protein
concentration; data are shown as mean ± SD. *p < 0.05
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Aberrant liver lipid metabolism and fatty liver disease
are significant contributors to the morbidity and mortal-
ity associated with obesity-related diabetes [44]. Treating
gestational diabetics through diet modification, exercise,
and drugs (e.g., insulin and oral anti-diabetic agents, in-
cluding metformin) improves maternal, fetal/neonatal,
and offspring outcomes [45]. In the non-pregnant state,
metformin enhances glucose regulation and lipid metab-
olism in obese women [19, 46] and diabetic/hyperinsuli-
nemic rodents [20, 47]. Although it has been safely used
for treating GDM in other countries since the 1970s
[48], metformin has only been regularly prescribed to
women with GDM in the US within recent years [49].
Similarly, treatment of GDM with metformin has re-
cently increased in Norway, Wales, and the rest of the
UK [50]. Evidence from randomized controlled trials
and observational studies revealing no adverse maternal
or fetal/neonatal effects in the short-term [51, 52] sup-
ports using metformin for GDM [18]. The 2013 MiG
trial comparing insulin vs. metformin for treating gesta-
tional diabetics confirmed the safety of metformin in
pregnancy and revealed no differences in either maternal
circulating hormones/metabolites, birth weight, or neo-
natal anthropometric measurements between the two
treatments [53]. The results of the MiG trial showed
only subtle effects of metformin on maternal lipid pa-
rameters associated with cardiovascular risk and no ef-
fects on cord blood (fetal) lipids [53]. However, invasive
antenatal lipid analyses, as reported herein, were not
performed.
Metformin improves hepatic lipid metabolism [19, 20].
In the non-pregnant state, metformin reverses fatty liver
disease in obese leptin-deficient mice [21], blocks hepatic
steatosis, liver inflammation, and fibrosis in a non-diabetic
nonalcoholic steatohepatitis (NASH) mouse model [54],
and counter-regulates diet-induced SREBP-1 and fatty
acid synthase (FASN) protein expression in a mouse
model [55]. Although maternal metformin administration
reversed HCAL diet-induced SREBP-1 protein expression
in maternal livers (Fig. 2), it had no effect on HCAL-
induced hepatic (total) triglyceride-associated FA levels
(Fig. 1a), fatty acid profile changes (Fig. 1b-e and Table 2)
or FA-related gene expression in maternal livers (Table 3).
In fact, metformin slightly increased total triglyceride-
associated FA levels in the maternal rat liver, a finding that
is consistent with the reported increase in circulating tri-
glyceride levels and atherogenic plasma values in women
with GDM who were treated with metformin vs. insulin
later in pregnancy [56]. These results suggest potentially
differential regulation of FA metabolism by metformin in
the pregnant and non-pregnant states. Alternatively, in
our study HCAL diet-induced changes in the maternal
liver might not have been significant enough to be modi-
fied by metformin, a higher dose of metformin might be
required in pregnancy, or the duration of metformin treat-
ment was too short to observe measurable changes. How-
ever, this same HCAL diet regimen induced both GDM
[25] and hyperinsulinemia [24] in pregnant rats.
Prenatal metformin exposure may affect the fetal com-
partment and lead to long-term programming effects on
fetal metabolism [57], which may be positive. We and
others have shown that maternal metformin exerts anti-
inflammatory effects [24, 54, 58, 59], including the re-
duction of cytokines/chemokines in the fetal plasma and
amniotic fluid in a rat model of diet-induced obesity/
metabolic syndrome [24]. Although we did not observe
significant HCAL-induced maternal liver-associated in-
flammation, elevated IFNγ concentrations were found in
the fetal livers, and these were attenuated by maternal
metformin administration (Fig. 6). Consistent with the fetal
programming effects of metformin, in utero metformin ex-
posure reversed diet-induced overall MUFA (Fig. 3c), as
well as HCAL-diet reduced n3 FA (Fig. 3e), 18:1n9 (oleic
acid) levels, and 22:6n3 (DHA) levels in fetal livers (Table 4).
Although not significant, metformin slightly attenuated
HCAL-induced D5d and D9d mRNA expression in the
fetal livers (Table 3). By contrast, except for 22:5n6 (a minor
phospholipid-fatty acid in the brain), in utero metformin
exposure had no effects on diet-induced FA changes in the
fetal brains (Table 5).
Our data show significant effects of maternal obesogenic-
diet exposure and metformin treatment during metabolic
syndrome in pregnancy on FA composition and FA metab-
olism in the fetal compartment. However, this study has
several limitations. Methodologically, the high calorie diet
was provided only 5 weeks prior to pregnancy and through-
out pregnancy (3 weeks) and thus, represents ‘acute diet-
induced obesity’. A longer HCAL diet-feeding period might
better reflect the chronic obesity observed in humans. Be-
cause the normal and HCAL diets (± metformin) were pro-
vided ad libitum we were unable to assess exact intakes.
Also, maternal metformin treatment was modeled after ro-
dent studies performed in the absence of pregnancy. Per-
haps higher doses of metformin are required during
pregnancy. Finally, these findings are difficult to extrapolate
to humans, which is true for all studies using laboratory
animals. Nevertheless, this model may provide us with
a better understanding of the pathophysiological changes
observed with maternal obesity/metabolic syndrome and
the use of metformin for obesity-related metabolic syn-
drome during pregnancy.
It is important to note that maternal metformin treat-
ment in humans does not compromise neurodevelopmental
outcomes when measured in two year old children [60, 61].
Our results show that metformin promotes preservation of
fetal DHA (despite reduced maternal liver DHA) important
for fetal/neonatal brain development. Recent studies by Sal-
omaki and co-workers revealed that the fetal liver is an
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important target of maternal metformin and that protective
effects on offspring were observed when dams were ex-
posed to a high fat diet (vs. normal diet) prior to/during
metformin treatment [57, 62]. Our study differs in that a
high fat, high sugar diet was administered to dams (prior
to/during metformin treatment) rather than a regular diet
[57] or a high fat diet [62]; the high fat, high sugar diet was
chosen to better reflect the Western diet. Although our
study was not designed to investigate the effects of a mater-
nal high calorie diet (±metformin) on long-term offspring
outcomes, the data support the potential fetal programming
effects of maternal obesity via changes in fetal fatty acid
profiles and fetal liver IFNγ concentrations, with reversal by
maternal metformin administration. Both GDM and adult
obesity are increasing [3, 4, 63] and thus, represent wide-
spread problems with potentially serious implications for
mothers and their offspring. Therefore, future studies will
focus on investigating the effects of metformin and other
anti-diabetic and/or lipid normalizing strategies in the set-
ting of obesity/metabolic syndrome during pregnancy on
neonatal complications and long-term adverse metabolic
consequences in the offspring. These studies would facilitate
the development of interventions to mitigate the adverse ef-
fects of maternal obesity and metabolic syndrome on off-
spring health in the short- and long-terms.
Conclusions
Obesogenic diet consumption by pregnant mice led to
changes in the fatty acid composition of maternal and fetal
livers, including reductions in healthy PUFAs and anti-
inflammatory n3 FAs. In utero HCAL diet exposure in-
creased liver IFNγ concentrations without affecting mater-
nal liver IFNγ concentrations. While maternal metformin
treatment did not significantly alter diet-induced maternal
liver fatty acid changes, fetal exposure to metformin atten-
uated diet-induced changes in fetal liver DHA levels, anti-
inflammatory n3FAs and liver IFNγ concentrations. Thus,
maternal metformin might be beneficial for fetal/neonatal
outcomes in the setting of maternal obesity and/or meta-
bolic syndrome.
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